Linklaters advises Apax Partners on the sale of Neuraxpharm
Linklaters has advised funds managed by Apax Partners on the sale of shares in Neuraxpharm, a leading European pharmaceutical company focusing on the treatment of central nervous system disorders, to funds advised by Permira. This is reported to be the biggest European pharma deal of 2020.
Neuraxpharm is active in 13 countries and covers around 80 percent of the European drug market for the treatment of central nervous system disorders. The company generates annual sales of more than 460 million euros and employs over 850 people.
The Linklaters team advising on the deal was led by private equity Partners Ben Rodham (London) and Ralph Drebes (Frankfurt) supported by private equity Managing Associates Ben Suen (London) and Nikita Selivanov (Frankfurt).
Linklaters advised Apax Partners on the acquisition of Neuraxpharm in 2016 (and several subsequent bolt-on transactions) and is Linklaters‘ latest high-profile advisory role in the healthcare sector, following on from the acquisition of UK-based biotech KaNDy Therapeutics Ltd, a leading UK-based biotech firm, by Bayer AG in August 2020.